Funding for this trial has been provided in full or in part by Cystic Fibrosis Foundation Therapeutics, Inc.
Study Phase:
4
Recruitment Status:
Trial Completed
Study Drug(s):
Ciprofloxacin (oral)
Number of Participants Being Recruited:
250
Single / Multi-Center:
Multi-Center
STUDY BACKGROUND INFORMATION:
This study will be done in Denmark, Sweden, and Norway. Two different medication therapies will be compared directly with one another to determine if either prevent the development of chronic pseudomonas aeruginosa lung infections. The one therapy will be 3 weeks of nebulized colistin + oral ciprofloxacin and azithromycin. The other therapy will be 3 weeks of nebulized colistin + oral ciprofloxacin. Participants will be have sputum or nasopharnyngeal cultures taken every 3 months for 2 years.
ELIGIBILITY
Age:
>= 1 Months
FEV1:
- Percent Predicted
P. aeruginosa status:
Positive
B. cepacia status:
Not applicable
Other Primary Eligibility Requirements:
Note: Detailed eligibility criteria information may be available on clinicaltrials.gov. If a specific
trial listing for this trial is available, a link to the specific clinicaltrials.gov listing will be present in the "More Information" section below.
